Metrics & Benchmarks

>

Latest News

Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations
Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations

July 17th 2025

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) safety and efficacy in pregnant women, young adults, and others historically excluded from HIV prevention studies.

Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 16th 2025

Iovance’s Amtagvi Shows Strong Effectiveness in Advanced Melanoma
Iovance’s Amtagvi Shows Strong Effectiveness in Advanced Melanoma

July 15th 2025

CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia

July 14th 2025

EMBARK Trial Shows Xtandi Combination Demonstrates Significant Overall Response in Non-Metastatic Hormone-Sensitive Prostate Cancer
EMBARK Trial Shows Xtandi Combination Demonstrates Significant Overall Response in Non-Metastatic Hormone-Sensitive Prostate Cancer

July 10th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.